Quizartinib (AC220) - ≥99%, high purity , CAS No.950769-58-1, Inhibitor of colony stimulating factor 1 receptor;Inhibitor of fms related receptor tyrosine kinase 3;Inhibitor of KIT proto-oncogene; receptor tyrosine kinase;Inhibitor of platelet derived growth factor receptor alpha;Inhibitor of platelet derived growth

Item Number
Q127558
Grouped product items
SKUSizeAvailabilityPrice Qty
Q127558-5mg
5mg
In stock
$64.90
Q127558-10mg
10mg
In stock
$90.90
Q127558-50mg
50mg
Available within 1-2 weeks(?)
Item is derived from our semi-finished stock and is processed in 1-2 weeks.
$155.90
Q127558-500mg
500mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$848.90

Potent, selective Flt3 inhibitor

Basic Description

SynonymsQuizartinib | 950769-58-1 | AC220 | Quizartinib (AC220) | AC-220 | AC 220 | Quizartinib HCl | AC010220 | vanflyta | Quizartinib freebase | 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea | AC 010220 | ASP-2689 | 7LA4O6Q0D3
Specifications & PurityMoligand™, ≥99%
Biochemical and Physiological MechanismsQuizartinib, Free Base, is an fms-related tyrosine kinase 3 (FLT3) receptor tyrosine kinase inhibitor. In binding assays, quizartinib has demonstrated a high affinity for FLT3 (Kd = 1.6 nM). in vitro assays examining FLT3 internal tandem duplicate mutatio
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of colony stimulating factor 1 receptor;Inhibitor of fms related receptor tyrosine kinase 3;Inhibitor of KIT proto-oncogene; receptor tyrosine kinase;Inhibitor of platelet derived growth factor receptor alpha;Inhibitor of platelet derived growth
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 3.
An Flt-3/Flk-2 inhibitor.

Associated Targets(Human)

CSF1R Tclin Macrophage colony-stimulating factor 1 receptor (7 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
RET Tclin Proto-oncogene tyrosine-protein kinase receptor Ret (13 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
FLT3 Tclin Receptor-type tyrosine-protein kinase FLT3 (43 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDGFRA Tclin Platelet-derived growth factor receptor alpha (7 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDGFRB Tclin Platelet-derived growth factor receptor beta (7 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
KIT Tclin Mast/stem cell growth factor receptor Kit (14 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MYH10 Tchem Myosin-10 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488200713
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488200713
IUPAC Name 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
INCHI InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
InChi Key CVWXJKQAOSCOAB-UHFFFAOYSA-N
Canonical SMILES CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
Isomeric SMILES CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
PubChem CID 24889392
Molecular Weight 560.68

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

6 results found

Lot NumberCertificate TypeDateItem
B2423037Certificate of AnalysisMar 01, 2024 Q127558
D2320861Certificate of AnalysisMar 15, 2023 Q127558
D2320868Certificate of AnalysisMar 15, 2023 Q127558
D2320869Certificate of AnalysisMar 15, 2023 Q127558
D2320885Certificate of AnalysisMar 15, 2023 Q127558
F1509079Certificate of AnalysisJan 25, 2023 Q127558

Chemical and Physical Properties

SolubilityDMSO 33.2 mg/mL; Water <0.3 mg/mL; Ethanol <0.5 mg/mL

Related Documents

References

1. Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J et al..  (2009)  Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor..  J Med Chem,  52  (23): (7808-16).  [PMID:19754199]

Solution Calculators